These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24238473)

  • 1. Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.
    de Toledo MC; Sarian LO; Sallum LF; Andrade LL; Vassallo J; de Paiva Silva GR; Pinto GA; Soares FA; Fonseca CD; Derchain SF
    Acta Histochem; 2014 Apr; 116(3):440-7. PubMed ID: 24238473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer.
    Liu N; Wang X; Sheng X
    J Clin Pathol; 2010 Mar; 63(3):240-3. PubMed ID: 20203223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
    Liu N; Wang X; Sheng X
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor status predicts development of brain metastases in ovarian cancers.
    Mittica G; Senetta R; Scotto G; Aglietta M; Maggiorotto F; Ghisoni E; Genta S; Boldorini R; Manini C; Morra I; Buosi R; Sapino A; Cassoni P; Valabrega G
    Oncotarget; 2017 Jun; 8(25):41143-41153. PubMed ID: 28467804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
    Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
    Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
    Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of triple negative epithelial ovarian cancer in indigenous African women.
    Ajani MA; Salami AA; Awolude OA; Oluwasola AO
    F1000Res; 2016; 5():2415. PubMed ID: 27853516
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
    Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.
    Lenhard M; Tereza L; Heublein S; Ditsch N; Himsl I; Mayr D; Friese K; Jeschke U
    BMC Cancer; 2012 Nov; 12():553. PubMed ID: 23176303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
    Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.
    Shafrir AL; Rice MS; Gupta M; Terry KL; Rosner BA; Tamimi RM; Hecht JL; Tworoger SS
    Gynecol Oncol; 2016 Dec; 143(3):628-635. PubMed ID: 27720231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
    Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
    Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of hormonal receptor status of malignant ovarian tumors.
    Tkalia IG; Vorobyova LI; Svintsitsky VS; Nespryadko SV; Goncharuk IV; Lukyanova NY; Chekhun VF
    Exp Oncol; 2014 Jun; 36(2):125-33. PubMed ID: 24980769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival.
    Gogola-Mruk J; Pietrus M; Piechowicz M; Milian-Ciesielska K; Głód P; Wolnicka-Glubisz A; Szpor J; Ptak A
    Reprod Biol; 2024 Sep; 24(3):100917. PubMed ID: 38970978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
    Ajani MA; Salami A; Awolude OA; Oluwasola AO
    Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
    García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
    Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
    Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
    Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.